Nearly two decades ago, a class of once-promising cancer drugs called MMP inhibitors mysteriously failed in clinical trials. Now scientists think they may have an explanation. A new study shows that when MMP enzymes are disabled, invasive cells can change their tactics. The findings in C. elegans worms could lead to better ways to prevent metastasis, the spread of the disease responsible for 90 percent of cancer deaths.